Hosted Inaugural R&D Day: THE BUSINESS provided a thorough update of its research and development applications at its 1st inaugural R&D Day in New York City on July 14, 2015. THE BUSINESS emphasized its goal of creating a new regular in gastrointestinal and cardio-renal care and supplied additional information regarding its robust medical program. Particular highlights included: Additional Phase 2b data for tenapanor in IBS-C demonstrating a durable or sustained responder price of 14.6 % greater than the placebo group Proof of concept study in an animal model of chemotherapy-induced diarrhea for RDX009, a TGR5 agonist that stimulates local secretion of GLP-2 and GLP-1 in the gut Proof of concept data demonstrating that RXD013, an oral potassium secretagogue, causes the secretion of potassium into the intestines in a preclinical model Related StoriesGenetic check that predicts recurrence of breasts cancer may impact use of chemotherapyMultigene test performed on tumor can identify breast cancer sufferers who can safely avoid chemotherapyChemotherapy-induced nausea and vomiting most common distressing symptoms in majority of cancer patientsSummary of Upcoming Clinical Milestones Initiation of a 12-week Phase 3 study of tenapanor in IBS-C patients in 4Q2015 Initiation of a Stage 2b research of tenapanor in hyperphosphatemia individuals on dialysis in 4Q2015 with outcomes expected in 2H2016 Initiation of pharmacodynamic study of RDX022 in 4Q2015 with outcomes expected in 1H2016 Initiation of a six-month Phase 3 research of tenapanor in IBS-C patients in 1H2016 Initiation of a Stage 3 scientific trial to judge RDX022 for the treatment of hyperkalemia in 2H2016 Planned submission of an IND for RDX009 in 2H2016 Second Quarter 2015 Financial Results Net income in the second one fourth of 2015 was $9.0 million, or $0.43 per simple and $0.42 per diluted share, compared to a net gain of $3.8 million, or $0.20 per simple and $0.18 per diluted share in the second quarter of 2014.All polyps were removed and examined by research pathologists. Towards the end of the trial, the cumulative adenoma price for the celecoxib study group was 33.6 %, while the cumulative rate of adenoma development in the placebo group was 49.3 % . Celecoxib administration was connected with a 50 % reduction in larger, more dangerous adenomas potentially. Related StoriesViralytics enters into medical trial collaboration agreement with MSDMeat-rich diet plan may increase kidney malignancy riskSausages With Antioxidants From Berries To Prevent Cancer’Unlike the recent Adenoma Avoidance with Celecoxib trial, we didn’t look for a statistically significant upsurge in cardiovascular risk associated with the usage of 400 mg of celecoxib once daily,’ said Levin.